Forthcoming receptor tyrosine kinase inhibitors

Bibliography

• BLUME-JENSEN P, HUNTER T: Oncogenic kinase signalling. Nature (2001) 411:355-365.
   PubMed Web of Science ®Google Scholar
• HEHLMANN R, BERGER U, HOCHHAUS A: Chronic myeloid leukemia: a model for oncology. Ann. Hematol. (2005) 84:487-497.
   PubMed Web of Science ®Google Scholar
• ROY L, GUILHOT J, KRAHNKE T et al.: Survival advantage from Imatinib compared to the combination Interferon-{alpha} plus cytarabine in chronic phase CML: historical comparison between two Phase III trials. Blood (2006) 108:1478-1484.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344:783-792.
   PubMed Web of Science ®Google Scholar
• VAN OOSTEROM AT, JUDSON I, VERWEIJ J et al.: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet (2001) 358:1421-1423.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, RODRIGUES PEREIRA J, CIULEANU T et al.: Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. (2005) 353:123-132.
   PubMed Web of Science ®Google Scholar
• DEMETRI GD, VON MEHREN M, BLANKE CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. (2002) 347:472-480.
   PubMed Web of Science ®Google Scholar
• COOLS J, DEANGELO DJ, GOTLIB J et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. (2003) 348:1201-1214.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351:337-345.
   PubMed Web of Science ®Google Scholar
• HERBST RS, JOHNSON DH, MININBERG E et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. (2005) 23:2544-2555.
   PubMed Web of Science ®Google Scholar
• VOKES EE, COHEN EE, MAUER AM et al.: A Phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2005) 23:Abstract 5504.
   Google Scholar
• SALTZ LB, LENZ H, HOCHSTER H et al.: Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J. Clin. Oncol. (2005) 23:Abstract 3508.
   Google Scholar
• ABRAMS TJ, LEE LB, MURRAY LJ, PRYER NK, CHERRINGTON JM: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. (2003) 2:471-478.
   PubMed Web of Science ®Google Scholar
• MENDEL DB, LAIRD AD, XIN X et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. (2003) 9:327-337.
   PubMed Web of Science ®Google Scholar
• ADNANE L, TRAIL PA, TAYLOR I, WILHELM SM: Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. (2005) 407:597-612.
   Web of Science ®Google Scholar
• ESCUDIER B, SZCZYLIK C, EISEN T et al.: Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). J. Clin. Oncol. (2005) 23:Abstract 4510.
   Google Scholar
• EISEN T, OUDARD S, SZCZYLIK C et al.: Clinical benefit of sorafenib in the elderly with advanced renal cell carcinoma: subgroup analysis of the approaches in renal cancer global evaluation trial (TARGETS). Ann. Oncol. (2006) 17:Abstract 446PD.
   Google Scholar
• MOTZER RJ, RINI BI, BUKOWSKI RM et al.: Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 295:2516-2524.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. (2006) 24:LBA3.
   Google Scholar
• RINI BI, GEORGE DJ, MICHAELSON MD et al.: Phase II study of sunitinib malate (SU11248) in bevacizumab-refractory metastatic renal cell carcinoma. Ann. Oncol. (2006) 17:Abstract 4380.
   Google Scholar
• TAMASKAR I, SHAHEEN P, WOOD L et al.: Antitumor effects of sorafenib and sunitinib in patients with metastatic renal cell carcinoma who had prior therapy with anti-angiogenic agents. J. Clin. Oncol. (2006) 24:Abstract 4597.
   Google Scholar
• KIM TE, MURREN JR: Lapatinib ditosylate GlaxoSmithKline. IDrugs (2003) 6:886-893.
   PubMedGoogle Scholar
• GEYER CE, FORSTER JK, CAMERON D et al.: A Phase III randomized, open-label, international study comparing lapatinib and capecitabine versus capecitabine in women with refractory advanced or metastatic breast cancer (EGF100151). Proc. Am. Soc. Clin. Oncol. (2006) Scientific Special Session.
   Google Scholar
• CAMERON D, GEYER CE, CHAN S et al.: Lapatinib in combination with capecitabine demonstrates superior efficacy compared with capecitabine alone in ERBB2+ advanced or metastatic breast cancer patients pretreated with chemotherapy and trastuzumab. Ann. Oncol. (2006) 17:Abstract 1410.
   Google Scholar
• LIN NU, CAREY LA, LIU MC et al.: Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. J. Clin. Oncol. (2006) 24:Abstract 503.
   Google Scholar
• PEREZ EA, BYRNE JA, HAMMOND IW et al.: Cardian safety experience in 3127 patients treated with lapatinib. Ann. Oncol. (2006) 17:Abstract 1420.
   Google Scholar
• NATALE RB, BODKIN D, GOVINDAN R et al.: ZD6474 versus gefitinib in patients with advanced NSCLC: final results from a two-part, double-blind, randomized Phase II trial. J. Clin. Oncol. (2006) 24:Abstract 7000.
   Google Scholar
• HEYMACH JV, JOHNSON BE, PRAGER D et al.: A Phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: follow-up results. J. Clin. Oncol. (2005) 24:Abstract 7016.
   Google Scholar
• KOBAYASHI S, BOGGON TJ, DAYARAM T et al.: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2005) 352:786-792.
   PubMed Web of Science ®Google Scholar
• SHAH NP, NICOLL JM, NAGAR B et al.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 2:117-125.
   PubMed Web of Science ®Google Scholar
• CHEN LL, TRENT JC, WU EF et al.: A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. (2004) 64:5913-5919.
   PubMed Web of Science ®Google Scholar
• CORBIN AS, LA ROSEE P, STOFFREGEN EP, DRUKER BJ, DEININGER MW: Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood (2003) 101:4611-4614.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, GILES F, WUNDERLE L et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. (2006) 354:2542-2551.
   PubMed Web of Science ®Google Scholar
• TALPAZ M, SHAH NP, KANTARJIAN H et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. (2006) 354:2531-2541.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, GATTERMANN N, O’BRIEN S et al.: A Phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia in chronic phase. J. Clin. Oncol. (2006) 24:Abstract 6534.
   Google Scholar
• LE COUTRE PD, OTTMANN O, GATTERMAN N et al.: A Phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP). J. Clin. Oncol. (2006) 24:Abstract 6531.
   Google Scholar
• CORTES JE, KIM DW, ROSTI G et al.: Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): results of the CA180006 ‘START-B’ study. J. Clin. Oncol. (2006) 24:Abstract 6529.
   Google Scholar
• SHAH NP, ROUSSELOT P, PASQUINI R et al.: Dasatinib (D) versus high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial. J. Clin. Oncol. (2006) 24:Abstract 6507.
   Google Scholar
• TALPAZ M, APPERLEY JF, KIM DW et al.: Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: results of the CA180005 ‘START-A’ study. J. Clin. Oncol. (2006) 24:Abstract 6526.
   Google Scholar
• HOCHHAUS A, KANTARJIAN H, BACCARANI M et al.: Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: results of the CA180013 ‘START-C’ Study. J. Clin. Oncol. (2006) 24:Abstract 6508.
   Google Scholar
• ESTROV Z, O’BRIEN S, GILES F et al.: Dasatinib (BMS354825), a dual Src-Abl inhibitor, is active in Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML) following treatment failure with imatinib mesylate and AMN107. J. Clin. Oncol. (2006) 24:Abstract 6530.
   Google Scholar
• REICHARDT P, CASALI PG, BLAY J et al.: A Phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST). J. Clin. Oncol. (2006) 24:Abstract 9545.
   Google Scholar
• SCHITTENHELM MM, SHIRAGA S, SCHROEDER A et al.: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. (2006) 66:473-481.
   PubMed Web of Science ®Google Scholar
• EVANS TR, MORGAN JA, VAN DEN ABBEELE AD et al.: Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. J. Clin. Oncol. (2005) 23:Abstract 3034.
   Google Scholar
• PAO W, MILLER V, ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA (2004) 101:13306-13311.
   PubMed Web of Science ®Google Scholar
• THATCHER N, CHANG A, PARIKH P et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet (2005) 366:1527-1537.
   PubMed Web of Science ®Google Scholar
• CLARK GM, CAMERON T, DAS GUPTA A: Clinical benefit of erlotinib in male smokers with squamous-cell NSCLC. J. Clin. Oncol. (2006) 24:Abstract 7166.
   Google Scholar
• EBERHARD DA, JOHNSON BE, AMLER LC et al.: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. (2005) 23:5900-5909.
   PubMed Web of Science ®Google Scholar
• PAZ-ARES L, SANCHEZ JM, GARCÍA-VELASCO A et al.: A prospective Phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J. Clin. Oncol. (2006) 24:Abstract 7020.
   Google Scholar
• MELLINGHOFF IK, WANG MY, VIVANCO I et al.: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. (2005) 353:2012-2024.
   PubMed Web of Science ®Google Scholar
• HEINRICH MC, CORLESS CL, DEMETRI GD et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. (2003) 21:4342-4349.
   PubMed Web of Science ®Google Scholar
• PAIK S, SHAK S, TANG G et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. (2004) 351:2817-2826.
   PubMed Web of Science ®Google Scholar